 BiondVax Pharmaceuticals Ltd. Nasdaq: BVXV, developer of the universal influenza vaccine candidate M-001, today published a reminder that its publicly traded warrants traded on Nasdaq under the symbol BVXVW will expire, according to their terms, on May 15, 2020. Warrants issued to underwriters in connection with our initial public offering in the United States will expire on May 11, 2020. 